EULAR 2024  | congress satellite symposia & consult-the-expert

A number of Satellite Symposia and Consult-The-Expert events will be organised during EULAR 2024, 12 June - 15 June. The Industry Programme e-booklet (PDF)*.

Satellite Symposia and Consult-The-Expert are governed by the EULAR Code of Practice, and are strictly prohibited during the official programme hours. All symposia and special events must be approved by EULAR.

SCHEDULE OVERVIEW

WEDNESDAY, 12 JUNE 2024

18:30 - 19:45 Satellite Symposia (8 parallel sessions)
15:45 - 16:15 Consult-The-Expert (1 session)

THURSDAY, 13 JUNE 2024

08:15 - 09:30 Satellite Symposia (7 parallel sessions)
09:45 - 10:15 Consult-The-Expert (3 parallel sessions)
15:00 - 15:30

Consult-The-Expert (2 parallel sessions)

17:30 - 18:45 Satellite Symposia (8 parallel sessions)

FRIDAY, 14 JUNE 2024

08:15 - 09:30 Satellite Symposia (5 parallel sessions)
09:45 - 10:15 Consult-The-Expert (3 parallel sessions)
17:30 - 18:45

Satellite Symposia (3 parallel sessions)

 

Satellite Symposia Programme overview

12 June I 18:30 – 19:45 CEST

AbbVie - The Great Quest for Disease Control in PsA​

Session details

 

12 June I 18:30 – 19:45 CEST

Alfasigma - ​JAK inhibitors in practice: unlocking the potential in the real world of RA

Session details

 

12 June I 18:30 – 19:45 CEST

AstraZeneca - Remission in SLE: paving the way to improved patient care​

Session details

 

12 June I 18:30 – 19:45 CEST

GSK - Advancing lupus care: acting early to reduce the risk of organ damage progression​

Session details

 

12 June I 18:30 – 19:45 CEST

Johnson & Johnson - Charting the long course of psoriatic arthritis​

Session details

 

12 June I 18:30 – 19:45 CEST

Novartis - The Great Scientific Debate: IL-1β Inhibition vs IL-1 Receptor Blockade in AOSD​

Session details

 

12 June I 18:30 – 19:45 CEST

Sobi - Crystallising Options: Overcoming Challenges in the Care of Severe Gout​

Session details

 

12 June I 18:30 – 19:45 CEST

UCB - A Visit to the RFuture: Maximising Impact by Personalised Treatment in RA

Session details

13 June I 08:15 – 09:30 CEST

BMS - What makes deucravacitinib TYK?

Session details

 

13 June I 08:15 – 09:30 CEST

Boehringer Ingelheim - Systemic sclerosis: addressing the challenges

Session details

 

13 June I 08:15 – 09:30 CEST

Eli Lilly - Dispelling common myths in Spondyloarthritis

Session details

 

13 June I 08:15 – 09:30 CEST

GSK - EGPA Care Reimagined: Biologics through the lens of RWE​

Session details

 

13 June I 08:15 – 09:30 CEST

Merck - Toll-Like Receptors: an evolving story in lupus

Session details

 

13 June I 08:15 – 09:30 CEST

Novartis - ​Revealing New Layers: How Targeting IL-17A is Shaping Rheumatic and Musculoskeletal Disease Management

Session details

 

13 June I 08:15 – 09:30 CEST

Pfizer - Expert perspectives: patient selection for tofacitinib in RA

Session details

 

13 June I 17:30 – 18:45 CEST

AbbVie - ​All Aboard!: Choosing the Right Tracks to Accelerate Patients With RA and SpA Toward Their Goals​

Session details

 

13 June I 17:30 – 18:45 CEST

AstraZeneca - The mission for remission: what is now possible for our patients?​

Session details

 

13 June I 17:30 – 18:45 CEST

BMS - ​CAR T therapy - bringing a decade of successful experience to patients with Autoimmune diseases​

Session details

 

13 June I 17:30 – 18:45 CEST

Boehringer Ingelheim - Tackling interstitial lung disease in patients with systemic sclerosis or rheumatoid arthritis

Session details

 

13 June I 17:30 – 18:45 CEST

CSL Vifor - Excellence in ANCA-associated vasculitis (AAV) – from diagnosis to optimal care

Session details

 

13 June I 17:30 – 18:45 CEST

Johnson & Johnson - The cycle of inflammation: IL-23 across psoriatic disease

Session details

 

13 June I 17:30 – 18:45 CEST

Pfizer - Expert perspectives: cross-speciality applications of tofacitinib in AS and UC

Session details

 

13 June I 17:30 – 18:45 CEST

UCB - ​Time to Revolutionise Clinical Practice? Striving for Resolution of Inflammation with the Dual Inhibition of IL-17A and IL-17F in PsA and axSpA​

Session details

14 June I 08:15 – 09:30 CEST
Cabaletta Bio - Immune Reset: The Potential of CAR T Cell Therapy to Transform the Treatment of Patients with Autoimmune Disease
Session details

14 June I 08:15 – 09:30 CEST

GSK - EGPA: Exploring the emerging evidence​

Session details

 

14 June I 08:15 – 09:30 CEST

Kyverna - Anti-CD19 CAR T-Cell Therapy in Rheumatologic Autoimmune Diseases and Beyond

Session details

 

14 June I 08:15 – 09:30 CEST

Medac - Optimizing methotrexate – how to achieve maximum results with the anchor drug of RA therapy

Session details

 

14 June I 08:15 – 09:30 CEST

Otsuka - ​What’s new in Lupus Nephritis: from guidelines to real-world practices​

Session details

 

14 June I 17:30 – 18:45 CEST

Amgen - ​What’s New in IgG4-Related Disease and Where Do We Go Next​

Session details

 

14 June I 17:30 – 18:45 CEST

AstraZeneca - Rheumatology meets pulmonology: holistic perspectives for EGPA​

Session details

 

14 June I 17:30 – 18:45 CEST

Sanofi - ​Unveiling the Clinical Canvas: Navigating Unmet Needs in Polymyalgia Rheumatica​

Session details

 

Consult-the-expert programme overview

12 June I 15:45 – 16:15 CEST

GSK - ​New Paths, New Crossroads: Seeing into Systemic Sclerosis​

Session details

13 June I 09:45 – 10:15 CEST
GSK - ​Seizing the Window of Opportunity in Lupus: How to Achieve Disease Modification​
Session details

13 June I 09:45 – 10:15 CEST

Johnson & Johnson - ​With a little help from my peers: challenging PsA cases in daily practice​

Session details

 

13 June I 09:45 – 10:15 CEST

Sobi - ​Macrophage Activation Syndrome in Still’s Disease – Current State and Future Horizons of Patient Management​

Session details

 

13 June I 15:00 – 15:30 CEST

GSK - Practical considerations when advancing lupus care​

Session details

 

13 June I 15:00 – 15:30 CEST

Novartis - ​FMF: the role of canakinumab in the treatment paradigm​

Session details

14 June I 09:45 – 10:15 CEST
AstraZeneca - Achieving disease control across organ systems – expert perspectives from the real world
Session details

14 June I 09:45 – 10:15 CEST

UCB - Unlock Your Digital Impact: Social Media Master Class

Session details

 

14 June I 09:45 – 10:15 CEST

GSK - The power of prevention: Why herpes zoster vaccination matters in patients with rheumatic diseases​

Session details